Lista de obras - Raffaele Califano - Dominio Público Uruguay

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours

artículo científico publicado en 2011

Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient Programme.

artículo científico publicado en 2014

Availability of EGFR mutation status at first oncology consultation for advanced non-squamous non-small cell lung cancer patients. A pilot experience from the Christie.

artículo científico publicado en 2013

Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.

artículo científico

Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma

artículo científico publicado en 2012

Can EBUS-TBNA provide an accurate diagnosis in patients found to have enlarged or FDG-avid lymph nodes during surveillance of previously treated lung cancer? A retrospective study.

artículo científico publicado en 2015

Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation.

artículo científico

Current and future therapeutic approaches for the treatment of small cell lung cancer.

artículo científico publicado en 2018

Durvalumab after chemo-radiotherapy in stage III non-small cell lung cancer.

artículo científico publicado en 2018

Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK

artículo científico publicado en 2015

First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light

scientific article published on 19 June 2019

Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer.

artículo científico publicado en 2016

Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios.

artículo científico publicado en 2018

Immune checkpoint blockade in small cell lung cancer

scientific article published on 22 August 2019

Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?

artículo científico publicado en 2016

Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms

artículo científico publicado en 2016

Lung cancer after treatment for breast cancer

artículo científico publicado en 2010

Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?

artículo científico publicado en 2016

Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.

artículo científico

Management of small cell lung cancer: recent developments for optimal care

artículo científico publicado en 2012

Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial

artículo científico publicado en 2011

Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis

artículo científico publicado en 2015

Outcomes of octogenarian (≥80 yo) patients with advanced non-small cell lung cancer (NSCLC): A single institution experience at the Christie Hospital

article

Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis

artículo científico publicado en 2010

Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer

artículo científico publicado en 2016

Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer

artículo científico publicado en 2008

Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer

artículo científico publicado en 2018

Prise en charge du cancer bronchique à petites cellules (CPC) (localisé et étendu)

Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey.

artículo científico publicado en 2017

Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group

artículo científico publicado en 2011

Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents

artículo científico publicado en 2015

SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting

artículo científico publicado en 2017

Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions

scientific article published on 24 September 2019

Targeted therapies in small cell lung cancer: a review

artículo científico publicado en 2010

The Role of Targeted Agents and Immunotherapy in Older Patients with Non-small Cell Lung Cancer

artículo científico publicado en 2018

The TORCH trial.

artículo científico publicado en 2012

The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO).

artículo científico

The role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas

artículo científico publicado en 2013

Therapies in the pipeline for small-cell lung cancer.

artículo científico publicado en 2016

Third-line chemotherapy in small-cell lung cancer: an international analysis.

artículo científico publicado en 2013

Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer

artículo científico

Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial

artículo científico publicado en 2011

Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): a European survey conducted by the European Society for Medical Oncology (ESMO) young oncologists committee.

artículo científico publicado en 2014

Lista de obras de Raffaele Califano

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours

Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient Programme.

Availability of EGFR mutation status at first oncology consultation for advanced non-squamous non-small cell lung cancer patients. A pilot experience from the Christie.

Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.

Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma

Can EBUS-TBNA provide an accurate diagnosis in patients found to have enlarged or FDG-avid lymph nodes during surveillance of previously treated lung cancer? A retrospective study.

Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation.

Current and future therapeutic approaches for the treatment of small cell lung cancer.

Durvalumab after chemo-radiotherapy in stage III non-small cell lung cancer.

Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK

First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light

Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer.

Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios.

Immune checkpoint blockade in small cell lung cancer

Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?

Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms

Lung cancer after treatment for breast cancer

Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?

Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.

Management of small cell lung cancer: recent developments for optimal care

Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial

Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis

Outcomes of octogenarian (≥80 yo) patients with advanced non-small cell lung cancer (NSCLC): A single institution experience at the Christie Hospital

Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis

Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer

Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer

Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer

Prise en charge du cancer bronchique à petites cellules (CPC) (localisé et étendu)

Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey.

Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group

Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents

SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting

Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions

Targeted therapies in small cell lung cancer: a review

The Role of Targeted Agents and Immunotherapy in Older Patients with Non-small Cell Lung Cancer

The TORCH trial.

The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO).

The role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas

Therapies in the pipeline for small-cell lung cancer.

Third-line chemotherapy in small-cell lung cancer: an international analysis.

Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer

Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial

Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): a European survey conducted by the European Society for Medical Oncology (ESMO) young oncologists committee.